Arsenic Exposure, Blood DNA Methylation, and Cardiovascular Disease-Reference-Cited by-同舟云学术

Arsenic Exposure, Blood DNA Methylation, and Cardiovascular Disease

Published:2022-07-08 Issue:2 Volume:131 Page:
ISSN:0009-7330
Container-title:Circulation Research
language:en
Short-container-title:Circ Res

Author:

Domingo-Relloso Arce¹²³^ORCID,Makhani Kiran⁴,Riffo-Campos Angela L.⁵⁶^ORCID,Tellez-Plaza Maria²^ORCID,Klein Kathleen Oros⁴,Subedi Pooja⁷,Zhao Jinying⁷,Moon Katherine A.⁸,Bozack Anne K.⁹^ORCID,Haack Karin¹⁰^ORCID,Goessler Walter¹¹^ORCID,Umans Jason G.¹²¹³^ORCID,Best Lyle G.¹⁴,Zhang Ying¹⁵,Herreros-Martinez Miguel¹⁶^ORCID,Glabonjat Ronald A.¹^ORCID,Schilling Kathrin¹^ORCID,Galvez-Fernandez Marta¹²^ORCID,Kent Jack W.¹⁰,Sanchez Tiffany R¹,Taylor Kent D.¹⁷^ORCID,Johnson W. Craig¹⁸^ORCID,Durda Peter¹⁹,Tracy Russell P.¹⁹^ORCID,Rotter Jerome I.¹⁷^ORCID,Rich Stephen S.²⁰^ORCID,Van Den Berg David²¹,Kasela Silva²²²³^ORCID,Lappalainen Tuuli²²²³,Vasan Ramachandran S²⁴²⁵^ORCID,Joehanes Roby²⁶²⁷^ORCID,Howard Barbara V.¹²¹³,Levy Daniel²⁶²⁷^ORCID,Lohman Kurt²⁸,Liu Yongmei²⁸,Fallin M Daniele²⁹,Cole Shelley A.¹⁰,Mann Koren K.⁴³⁰,Navas-Acien Ana¹^ORCID

Affiliation:

1. Department of Environmental Health Sciences, Columbia University Mailman School of Public Health, New York, NY (A.D.-R., R.A.G., K.S., M.G.-F., T.R.S., A.N.-A.).

2. Integrative Epidemiology Group, Department of Chronic Diseases Epidemiology, National Center for Epidemiology, Carlos III Health Institute, Madrid, Spain (A.D.-R., M.T.-P., M.G.-F.).

3. Department of Statistics and Operations Research (A.D.-R.), University of Valencia, Spain.

4. Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, Quebec, Canada (K.M., K.O.K., K.K.M.).

5. Department of Computer Science, ETSE (A.L.R.-C.), University of Valencia, Spain.

6. Millennium Nucleus on Sociomedicine (SocioMed) and Vicerrectoría Académica, Universidad de La Frontera, Temuco, Chile (A.L.R.-C.).

7. Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville (P.S., J.Z.).

8. Department of Environmental Health and Engineering, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD (K.A.M.).

9. Department of Environmental Health Sciences, School of Public Health, University of California, Berkeley (A.K.B.).

10. Population Health Program, Texas Biomedical Research Institute, San Antonio‚ TX (K.H., J.W.K., S.A.C.).

11. Institute of Chemistry - Analytical Chemistry for Health and Environment, University of Graz, Austria (W.G.).

12. MedStar Health Research Institute, Hyattsville, MD. Now with Georgetown-Howard Universities Center for Clinical and Translational Science, Washington, DC (J.G.U., B.W.H.).

13. Georgetown-Howard Universities Center for Clinical and Translational Science, Washington, DC (J.G.U., B.V.H.).

14. Missouri Breaks Industries and Research, Inc, Eagle Butte, SD (L.G.B.).

15. Department of Biostatistics and Epidemiology, The University of Oklahoma Health Sciences Center (Y.Z.).

16. Bioinformatics Unit, Institute for Biomedical Research INCLIVA, Valencia, Spain (M.H.-M.).

17. The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, CA (K.D.T., J.I.R.).

18. Department of Biostatistics, University of Washington, Seattle (W.C.J.).

19. Department of Pathology Laboratory Medicine, Larner College of Medicine, University of Vermont, Burlington, VT (P.D., R.P.T.).

20. Center for Public Health Genomics, Department of Public Health Sciences, University of Virginia, Charlottesville, VA (S.S.R.).

21. Department of Population and Public Health Sciences, Keck School of Medicine of USC, University of Southern California, Los Angeles‚ CA (D.V.D.B.).

22. New York Genome Center (S.K., T.L.).

23. Department of Systems Biology, Columbia University‚ NY (S.K., T.L.).

24. National Heart, Lung, and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, MA (R.S.V.).

25. Sections of Preventive Medicine and Epidemiology and Cardiovascular Medicine, Department of Medicine, Department of Epidemiology, Boston University Schools of Medicine and Public Health, MA (R.S.V.).

26. Population Sciences Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD (R.J., D.L.).

27. Framingham Heart Study, MA (R.J., D.L.).

28. Department of Medicine, Duke University Medical Center, Durham, NC (K.L., Y.L.).

29. Departments of Mental Health and Epidemiology, Johns Hopkins University, Baltimore, MD (M.D.F.).

30. Department of Pharmacology and Therapeutics, McGill University, Montreal, Canada (K.K.M.).

Abstract

Background:Epigenetic dysregulation has been proposed as a key mechanism for arsenic-related cardiovascular disease (CVD). We evaluated differentially methylated positions (DMPs) as potential mediators on the association between arsenic and CVD.Methods:Blood DNA methylation was measured in 2321 participants (mean age 56.2, 58.6% women) of the Strong Heart Study, a prospective cohort of American Indians. Urinary arsenic species were measured using high-performance liquid chromatography coupled to inductively coupled plasma mass spectrometry. We identified DMPs that are potential mediators between arsenic and CVD. In a cross-species analysis, we compared those DMPs with differential liver DNA methylation following early-life arsenic exposure in the apoE knockout (apoE−/−) mouse model of atherosclerosis.Results:A total of 20 and 13 DMPs were potential mediators for CVD incidence and mortality, respectively, several of them annotated to genes related to diabetes. Eleven of these DMPs were similarly associated with incident CVD in 3 diverse prospective cohorts (Framingham Heart Study, Women’s Health Initiative, and Multi-Ethnic Study of Atherosclerosis). In the mouse model, differentially methylated regions in 20 of those genes and DMPs in 10 genes were associated with arsenic.Conclusions:Differential DNA methylation might be part of the biological link between arsenic and CVD. The gene functions suggest that diabetes might represent a relevant mechanism for arsenic-related cardiovascular risk in populations with a high burden of diabetes.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cardiology and Cardiovascular Medicine,Physiology

Reference115 articles.

1. Global threat of arsenic in groundwater

2. Arsenic, metals, fibres, and dusts.;IARC Working Group.;IARC Monogr Eval Carcinog Risks Hum,2012

3. Low-moderate urine arsenic and biomarkers of thrombosis and inflammation in the Strong Heart Study

4. National Research Council. Critical aspects of EPA’s IRIS assessment of inorganic arsenic: Interim report. National Academies Press; 2013.

5. Dose-Response Relationship Between Ischemic Heart Disease Mortality and Long-term Arsenic Exposure

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Zexieyin formula alleviates atherosclerosis with cognitive impairment: A novel role in the treatment of comorbidities and its underlying mechanisms;Journal of Ethnopharmacology;2024-04

2. Intrauterine arsenic exposure induces glucose metabolism disorders in adult offspring by targeting TET2-mediated DNA hydroxymethylation reprogramming of HNF4α in developing livers, an effect alleviated by ascorbic acid;Journal of Hazardous Materials;2024-03

3. Prenatal arsenite exposure alters maternal cardiac remodeling during late pregnancy;Toxicology and Applied Pharmacology;2024-02

4. Marking Time: Epigenetic Aging May Partially Explain the Arsenic–Cardiovascular Disease Link;Environmental Health Perspectives;2024-02

5. Cardiovascular adverse effects and mechanistic insights of arsenic exposure: a review;Environmental Chemistry Letters;2024-01-09